The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — has been resolved.

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market share in incretin products as manufacturing continues to expand, while noting the drugmaker could start to benefit heading into third quarter earnings.

Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug Zepbound, can now meet present and projected national demand, the FDA said in a statement.

Ozempic and other diabetes-weight loss drugs have been linked to at least 162 deaths and 10,000 cases involving “serious” injuries since

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications.

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized on the pinch, are tumbling.

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.